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AbstrACt
Introduction Partner notification (PN) is a process aiming 
to identify, test and treat the sex partners of people (index 
patients) with sexually transmitted infections (STIs). 
Accelerated partner therapy (APT) is a PN method whereby 
healthcare professionals assess sex partners, by telephone 
consultation, before giving the index patient antibiotics 
and STI self- sampling kits to deliver to their sex partner(s). 
The Limiting Undetected Sexually Transmitted infections 
to RedUce Morbidity programme aims to determine the 
effectiveness of APT in heterosexual women and men 
with chlamydia and determine whether APT could affect 
Chlamydia trachomatis transmission at population level.
Methods and analysis This protocol describes a cross- 
over cluster randomised controlled trial of APT, offered 
as an additional PN method, compared with standard 
PN. The trial is accompanied by an economic evaluation, 
transmission dynamic modelling and a qualitative process 
evaluation involving patients, partners and healthcare 
professionals. Clusters are 17 sexual health clinics in 
areas of England and Scotland with contrasting patient 
demographics. We will recruit 5440 heterosexual women 
and men with chlamydia, aged ≥16 years.
The primary outcome is the proportion of index patients 
testing positive for C. trachomatis 12-16 weeks after the 
PN consultation. Secondary outcomes include: proportion 
of sex partners treated; cost effectiveness; model- 
predicted chlamydia prevalence; experiences of APT.
The primary outcome analysis will be by intention- to- 
treat, fitting random effects logistic regression models 
that account for clustering of index patients within 
clinics and trial periods. The transmission dynamic 
model will be used to predict change in chlamydia 
prevalence following APT. The economic evaluation will 
use mathematical modelling outputs, taking a health 
service perspective. Qualitative data will be analysed 
using interpretative phenomenological analysis and 
framework analysis.
Ethics and dissemination This protocol received 
ethical approval from London—Chelsea Research Ethics 
Committee (18/LO/0773). Findings will be published with 
open access licences.
trial registration number ISRCTN15996256.
strengths and limitations of this study
 ► The trial will evaluate accelerated partner therapy 
(APT), a novel approach to partner notification (PN), 
designed to facilitate and accelerate testing and 
treatment of sex partners of people with chlamydia.
 ► The primary outcome, chlamydia positivity, is ob-
jectively measured and clinically relevant, given its 
negative impact on both individual health outcomes 
and NHS (National Health Service) costs.
 ► This clinic- wide low- risk intervention has been 
granted ethical approval at the service- level without 
need for individual consent and complies with GDPR 
(General Data Protection Regulation).
 ► The pragmatic trial design will ensure that the effec-
tiveness of APT is evaluated under real- life clinical 
conditions.
 ► An integral process evaluation will capture any vari-
ations in the operationalisation of PN and APT at the 
local level and enable optimisation of APT proce-
dures in any future roll- out.
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IntroduCtIon
Partner notification (PN) is the process of identifying, 
testing and treating sex partners of a person with a sexu-
ally transmitted infection (STI).1 PN is a key element of 
STI control on several levels.2 It should benefit the indi-
vidual diagnosed with the STI (the index patient) by 
preventing re- infection, the sex partner who might be the 
source of infection or could transmit undiagnosed infec-
tions to new sexual partners, and it should help to reduce 
spread of STIs in sexual networks and populations.
STIs are a major public health concern. The sexually 
transmitted pathogen Chlamydia trachomatis causes chla-
mydia infection, the most commonly reported bacte-
rial STI in Britain,3–5 with 218 095 diagnosed cases in 
England in 2018.3 Untreated chlamydial infection can 
lead to pelvic inflammatory disease (PID), infertility, 
ectopic pregnancy and chronic pelvic pain in women.6 
In prospective studies with active follow- up, about 20% of 
women have a repeat diagnosis of chlamydia infection in 
the year after treatment.7–9
Chlamydia screening programmes aim to reduce the 
occurrence of complications by detecting and treating 
infections. For example, the incidence of diagnosed chla-
mydia in England has increased because of increases in 
both testing and transmission.3 10–12 Chlamydia control 
activities in England include a National Chlamydia 
Screening Programme, which offers chlamydia testing to 
sexually active adults aged under 25 years, who accounted 
for 61% of diagnosed chlamydia infections in 2018.13 
The Public Health Outcomes Framework in England sets 
targets to increase chlamydia diagnosis in young men 
and women.14 However a mathematical modelling study 
suggested that improving PN outcomes for chlamydia 
would be more cost effective than increasing the coverage 
of chlamydia testing,2 emphasising the importance of 
optimising the effectiveness of PN whatever the coverage 
of testing.
Like many other bacterial STIs, chlamydia does not 
induce lasting immunity after antibiotic treatment, and 
this represents a particular challenge for STI control 
efforts. Repeated infection after treatment can result from 
re- infection from an untreated partner, indicating failed 
PN, or from a new infection from a new partner. Alter-
natively, infection might persist if antibiotic treatment is 
not effective for any reason. It is usually not possible to 
determine the reason for the repeat positive test (re- in-
fection, new infection or treatment failure). In a mathe-
matical modelling study, the peak incidence of repeated 
infections was estimated at 2–5 months after treatment.15
Given the importance of PN in the control of STIs such 
as chlamydia, there is a need to optimise sexual health 
services’ support for effective PN. Currently, health-
care professionals in British sexual health services often 
struggle to meet modest targets.16–18 The PN process is 
challenging both for patients who may face barriers to 
informing sex partner(s) about the STI, and to services 
where trained staff need time to elicit sensitive informa-
tion from patients in order to support PN.
Offering patients alternatives, so that they can choose 
the most acceptable PN method—which might differ 
between sex partners—is considered optimal practice.19 
For people with chlamydia, PN is most often performed 
through patient referral,20 21 in which a healthcare profes-
sional advises the person with a diagnosed infection (the 
index patient) to inform their sex partner(s) of the need 
for testing and treatment and to refer them to a sexual 
health service (simple patient referral). This basic advice 
can be supplemented by information, in the form of 
written leaflets or website addresses, for the index patient 
to give to their partner(s) (enhanced patient referral). 
Expedited partner therapy (EPT) is a strategic approach 
to enhanced patient referral, widely adopted in USA, in 
which a healthcare professional gives the index patient 
antibiotics or a prescription for their partner(s).22 A 
systematic review found that EPT results in lower propor-
tions of index cases with repeated curable STIs than 
simple patient referral,16 and a US study demonstrated 
decreases in chlamydia positivity and gonorrhoea inci-
dence at the population level.23 However, EPT, as now 
widely practised in USA, does not require a consulta-
tion with the sex partner and does not comply with UK 
prescribing guidance,24 so cannot be implemented in UK.
We therefore developed accelerated partner therapy 
(APT) as an adaptation of EPT to speed up the enhanced 
patient referral process.25–27 APT complies with UK 
prescribing guidance since a healthcare professional 
assesses the appropriateness of the prescribed antibiotics 
for the partner.28 In brief, the healthcare professional 
performs a telephone consultation with the sex partner 
in private during the index patient’s clinic attendance. If 
medically safe, the index patient receives an APT pack, 
containing antibiotics and self- sampling kits for STI and 
HIV to deliver to their sex partner(s), or the clinic may 
post the APT pack to the sex partner(s). In pilot studies, 
APT resulted in faster sex partner treatment and greater 
overall numbers of sex partners treated, when compared 
with standard PN, but lower levels of testing for HIV and 
other STIs, when offered without HIV testing as part of 
the pack.25 26
In the trial described here, we aimed to compare strate-
gies for PN, specifically APT with routine PN approaches 
as currently practised in UK. As part of the Limiting 
Undetected Sexually Transmitted infections to RedUce 
Morbidity (LUSTRUM) programme ( lustrum. org. uk), we 
designed a randomised controlled trial (RCT) to deter-
mine the effects of APT for people with C. trachomatis on 
biological, as well as patient- reported clinical outcomes. 
Specific objectives are to determine: (1) the effect of APT 
on the proportion of index patients who test positive for 
chlamydia 12–16 weeks after the PN consultation; (2) the 
effect of APT on the proportion of sex partners treated; 
(3) the cost effectiveness of APT on long- term sexual 
and reproductive health outcomes, based on a linked 
transmission dynamic modelling study; (4) the effects of 
APT according to sex partner type; (5) whether APT is 
associated with faster treatment than standard PN; (6) 
copyright.
 o
n
 April 8, 2020 at Universitaetsbibliothek Bern. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034806 on 29 March 2020. Downloaded from 
3Estcourt CS, et al. BMJ Open 2020;10:e034806. doi:10.1136/bmjopen-2019-034806
Open access
Figure 1 Index patient and sex partner pathways during control and intervention arms. *Random allocation to intervention 
or control arm in the first phase of the trial. †Index patients and sex partners are notified of results via two pathways: (1) 
negative results: individual receives a text from The Doctors Laboratory; (2) positive/equivocal results: individual receives results 
directly from clinic. APT, accelerated partner therapy; HCP, healthcare professional; LUSTRUM, Limiting Undetected Sexually 
Transmitted infections to RedUce Morbidity; PN, partner notification.
the effects of APT on transmission of chlamydia at the 
population level, based on mathematical modelling; and 
to conduct: (7) a comprehensive process evaluation to 
understand the experiences of healthcare professionals, 
patients and sex partners of APT.
MEthods And AnAlysIs
trial design
LUSTRUM is a cross- over cluster RCT of APT offered as 
an additional PN method compared with standard PN 
alone. The APT intervention is offered at the level of the 
sexual health clinic, with randomisation of each clinic to 
either intervention or control arm in the first phase of the 
trial. The trial design is summarised in figure 1.
settings
Seventeen NHS (publicly funded, free to access) 
specialist sexual health clinics (clusters) across England 
and Scotland with high volumes of positive C. trachomatis 
test results and with contrasting patient demographics. 
Clinics were selected from those expressing interest, 
based on numbers of reported chlamydia diagnoses data 
in the Public Health England Genitourinary Medicine 
Clinical Activity Dataset for STI surveillance (England) 
and geographical diversity (Scotland) to create three 
strata: London, non- London metropolitan ‘cities’ and 
non- London urban ‘towns’. A full list of study sites is 
included in the Acknowledgments.
Eligibility criteria for index patients
Aged 16 years or older, positive test for C. trachomatis 
and/or clinical diagnosis of PID or cervicitis (women) or 
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box 1 overview of accelerated partner therapy (APt) for 
index patients
1. Index patient has partner notification (PN) consultation with health-
care professional (HCP); HCP assesses eligibility for APT.
2. Eligible index patient is offered APT alongside the clinic’s other 
standard PN options. The patient can choose different methods for 
different partners.
3. Index patient telephones or messages sex partner (with or without 
the HCP present, according to preference) to offer immediate tele-
phone assessment by the HCP.
4. Index patient waits in clinic while the HCP conducts APT telephone 
consultation in private with sex partner.
5. Index patient is informed that they will receive a follow- up tele-
phone call in 2 weeks and they will either receive a chlamydia 
self- sampling postal kit in 12–16 weeks (preferred), or they may 
re- attend the clinic for testing.
6. Two- week follow- up: research health adviser (RHA) telephones in-
dex patient to find out about PN outcomes with partner(s), to remind 
them of the repeat test, and to invite them to be contacted about 
taking part in a telephone interview regarding their experiences of 
APT (process evaluation).
7. 12 weeks: index patient is sent a personalised text reminder about 
repeat test.
8. 13 weeks: index patient is sent a self- sample kit by The Doctors 
Laboratory (TDL). Index patient returns self- collected sample or at-
tends clinic for repeat testing. S/he receives results either via text 
message from TDL (negative results) or using routine clinic systems 
(positive or equivocal results). Positive results are managed accord-
ing to routine clinic protocol. If the index patient does not return a 
self- sample or attend clinic for repeat testing, they receive a per-
sonalised text reminder 8 days after the self- sample kit is sent out, 
followed by a telephone call from the RHA 13 days after the self- 
sample kit is sent out. Self- samples received >24 weeks post- PN 
interview are excluded.
non- gonococcal urethritis (NGU) or epididymo- orchitis 
(men) and report at least one contactable sexual partner 
in the past 6 months. Index patients with PID, cervicitis, 
NGU and epididymo- orchitis whose test results are subse-
quently found to be negative for C. trachomatis will not 
be included in statistical analysis. Exclusion criteria are: 
groups of patients with more complex PN requirements; 
co- infection with other STIs including HIV, men who have 
had sex with men in the past 6 months, and patients who 
have paid for or who have been paid for sex in the past 6 
months. Patients with any clinical, social or other circum-
stances, such as sexual assault or insufficient English 
language skills to safely engage in telephone consulta-
tions, which emerge during the face- to- face consultation 
and make APT unsuitable will also be excluded.
Eligibility criteria for sex partners
Named as a sex partner of the index patient within the 
appropriate look back period (6 months for chlamydia, 3 
months for PID, 1 month for NGU)29 and selected by the 
index patient for APT and aged 16 years or older.
Intervention
The APT intervention is a complex intervention involving 
index patient, healthcare professional and sex partner, 
situated within wider clinical care (figure 1). In quali-
tative research studies to optimise the intervention, we 
explored the acceptability of individual components of 
the APT intervention with members of the public, sexual 
health clinic attenders and healthcare professionals.30 
During the intervention phase, clinics will offer APT as 
an additional option for eligible patients, alongside stan-
dard PN, described in box 1 for index patients, and box 2 
and figure 2 for sex partners. Eligible index patients who 
receive standard PN will receive the same follow- up as 
those who receive APT. If APT is no longer feasible (eg, 
sex partner unavailable), standard PN will be offered 
instead.
Control
During the control phase, each clinic follows their usual 
protocols for standard PN. All clinics conduct enhanced 
patient referral, including verbal information about noti-
fying partners plus additional information (written leaflets 
or signposting to a website). The healthcare professional 
will occasionally notify partners on behalf of the patient, 
if requested. Follow- up telephone calls and repeat testing 
will be the same as those during the APT phase.
outcomes
The primary clinical outcome is the proportion of index 
patients with a positive test result for C. trachomatis 12–16 
weeks after the PN consultation. A repeated positive test 
result after treatment is a proxy for re- infection from 
an untreated partner, assuming that other reasons for a 
repeat positive test result are distributed equally between 
intervention and control arms. This outcome has been 
used in RCTs of PN interventions seeking to demonstrate 
prevention of transmission at the level of the individual.16
Secondary clinical outcomes are: (1) the proportion of 
sex partners treated 2 weeks after the initial PN consulta-
tion; (2) numbers of partners treated per index patient; 
(3) time to partner treatment and (4) number of patients 
notified per index patient. These outcomes will be ascer-
tained by index patient reports at the 2- week follow- up 
telephone call with the research health adviser (RHA). 
Additional secondary outcomes include exploring the 
acceptability of the APT intervention to index patients 
and sex partners through qualitative telephone interviews 
with patients and partners as part of the process evalua-
tion. We will determine rates of STI and HIV testing in 
sex partners and proportions of positive test results for 
STIs and HIV among sex partners who return postal 
self- sampling kits contained in APT packs. We will deter-
mine costs associated with the intervention in economic 
evaluation studies based on costings of the trial. We will 
record any adverse events using local activity logs at each 
trial site and report them to the trial sponsor and ethics 
committee.
sample size
The trial is designed to determine superiority of APT as an 
adjunct to standard PN compared with standard PN. Our 
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box 2 overview of accelerated partner therapy (APt) for 
sex partners
1. Index patient telephones sex partner to inform them about exposure 
to chlamydia and offer immediate telephone assessment (APT).
2. If sex partner agrees to APT, healthcare professional (HCP) tele-
phones them and conducts a clinical assessment in private. If ap-
propriate, sex partner is offered an APT pack (delivered by the index 
patient or mailed directly). Sex partners for whom APT is inappropri-
ate or who do not wish to continue with the APT option, will be ad-
vised by the HCP to attend clinic for further management. During the 
same telephone call, HCP invites sex partner to be contacted about 
taking part in a telephone interview regarding their experiences of 
APT (process evaluation).
3. Sex partner receives APT pack (figure  2), which contains: antibi-
otics (either azithromycin or doxycycline, depending on local clinic 
practice); condoms; information about chlamydia, gonorrhoea, HIV 
and syphilis; chlamydia and gonorrhoea self- sampling kit, HIV and 
syphilis self- sampling kit, and information leaflet about how to take 
a sample (including link to an explanatory online video: lustrum.org.
uk/test- and- treat); request form for the sample to be processed 
by the lab; envelope for return of self- sampling kits and APT pack 
packaging (envelope or small box, no branding or other identifiable 
markings, and which fits through standard letterbox).
4. Sex partner completes self- sampling, labels and returns samples 
for testing.
5. Sex partner takes antibiotic treatment.
6. Sex partner informed of test results by text (negative results) or 
routine clinic processes; positive results are managed according to 
routine care.
Figure 2 Contents of sex partner accelerated partner 
therapy pack. Pack contains: antibiotics; condoms; Limiting 
Undetected Sexually Transmitted infections to RedUce 
Morbidity TEST & TREAT leaflet; vulvo- vaginal swab kit or 
urine sampling kit; blood sampling kit; instruction leaflet 
for sampling kits; test request form for sample processing; 
prepaid return post envelope; security seal sticker; attention 
card.
calculation is based on recruiting an average of 160 index 
patients per clinic per trial phase from the 17 participating 
clinical services (total 5440 patients) and a coefficient of 
variation in the number recruited of 0.5. We expect that 
50% of recruited patients (80 per clinic per phase and 
2720 total) will contribute to the analysis of the primary 
outcome because we restrict this analysis to patients with 
C. trachomatis detected at baseline. We assume that 60% of 
index patients will provide a repeat sample for C. tracho-
matis detection and we expect that 10%–25% of patients 
in the control arm will have C. trachomatis detected at the 
12–16 weeks follow- up.16 31 32 This sample size provides 
80% power (at the 5% significance level) to detect a 
fall in C. trachomatis positivity from 10% to 5%, and 82% 
power to detect a fall from 25% to 17%. We consider such 
reductions would be reasonable if around half the index 
patients in the intervention phase select APT for some 
or all their partners, but our calculation does not assume 
any specific value of APT uptake. A period of 6 months 
in the control condition and 6 months in the interven-
tion condition should be sufficient to reach this target. 
Related to our key secondary outcome (the proportion of 
sex partners treated), for simplicity, we consider power to 
detect an effect on the proportion of index patients with 
one or more partner treated. This sample size provides 
87% power to detect an increase from 60% in the control 
arm to 70% in the intervention arm.17
Sample size calculations are guided by Giraudeau et al33 
and performed as if the trial were a standard cluster RCT 
with 17 clinics in each arm. The cross- over design in our 
trial, with each cluster contributing data to both inter-
vention and control conditions, gives more information 
about the intervention effect and so greater power than 
stated above. Our calculations assume an intracluster 
correlation (ICC) of 0.02, which is not based on published 
data. We believe that our power calculations are likely to 
be conservative because any loss from a higher ICC will be 
more than offset by the gain from the cross- over design.
recruitment
During the initial PN consultation with the index patient, 
the healthcare professional will assess eligibility for the 
study for all patients with a laboratory positive test result 
for chlamydia or a clinical diagnosis of NGU/epididymo- 
orchitis (men) or PID/cervicitis (women). During the 
intervention phase, the healthcare professional will offer 
eligible patients APT in addition to standard methods of 
PN. The trial data manager will monitor recruitment and 
patient uptake of the APT intervention throughout the 
trial period supplying monthly recruitment figures to the 
Trial Management Group (TMG) and Data Monitoring 
Committee (DMC).
randomisation/allocation sequence
The random allocation of clinics, to intervention or 
control arm first, was conducted through random permu-
tation within strata, using computer- generated random 
numbers in Stata V.15 software. In four strata, the two 
clinics were part of one NHS trust and were considered as 
pairs. One stratum contained five clinics from large cities 
and another contained three clinics from smaller settle-
ments. Given the odd numbers of clinics in these strata, 
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we used random assignment to determine whether two or 
three clinics would implement the intervention first in the 
larger stratum (correspondingly two or one in the smaller 
stratum to ensure balance). One further clinic, the last 
(17th) to start recruitment was allocated through simple 
randomisation, giving a total of nine clinics allocated to 
implement the intervention first and eight to first follow 
routine practice. To remove the potential for allocation 
bias arising because allocation codes were generated 
after clinics had already been recruited to the trial, one 
statistician generated the allocation codes and another 
randomly permuted the clinic names within the strata. 
Only then, a third person matched the two to reveal the 
allocations and inform the clinic manager.
blinding
Blinding of allocation will not be possible for healthcare 
professionals, patients or research staff. A statistician 
blinded to allocation will replicate the analysis of the 
primary outcome.
Procedure for collecting data
Healthcare professionals will record their consultations 
in real time and download data needed for clinical 
purposes into the patient’s clinic record. They will use 
RELAY, a bespoke data collection tool. RELAY is a secure 
web- based data collection platform, which incorporates 
different interfaces allowing specified levels of access 
to healthcare professionals, RHAs, data manager, trial 
manager and the research team. It is hosted on secure 
servers and compliant with NHS data storage require-
ments. We developed RELAY for the LUSTRUM trial, 
based on previous versions of data collection tools in our 
pilot studies of APT.25 26
statistical analysis
Analysis will be by intention- to- treat. For the primary, and 
other quantitative outcomes, we will fit random effects 
models with fixed effects for clinic and intervention condi-
tion, together with a random effect to acknowledge the 
clustering of index patients for each combination of clinic 
and for each period.34 The primary and key secondary 
outcomes are binary, so we will use logistic regression 
models. The intervention effect will be expressed as an 
OR with 95% CI. Models for secondary outcomes with 
outcomes quantified for each sexual contact will include 
additional random effects for the index patient.
We anticipate loss to follow- up of around 40% of 
participants, raising potential concerns over bias. Before 
conducting our analysis of the primary outcome we will 
analyse predictors of follow- up from among a prespeci-
fied list of characteristics of the index patients that will 
be recorded at baseline and which are considered to be 
likely predictors of the primary outcome. In the primary 
analysis of the primary outcome we will include these as 
covariates in our regression model along with any other 
key predictors of the outcome. This approach should 
reduce bias from loss to follow- up but we will also conduct 
further sensitivity analyses based on multiple imputa-
tion in which we will allow those lost to follow- up to be 
more, and then less, likely to be chlamydia positive at 3 
months than those not lost to follow- up with the same 
baseline covariates. These sensitivity analyses will follow 
the approach of Carpenter et al,35 to assess the robustness 
of our conclusions to different prespecified assumptions 
about missing data.
Exclusions from analyses
The intervention is implemented at the clinic level and 
applied to all eligible patients with service- level, rather 
than individual, consent. Patients can opt- out of their 
data being used for research (see online supplementary 
file 1). Once a clinic has begun the allocated interven-
tion then all eligible patients added to the RELAY web 
tool will be included in analysis, following the spirit of an 
intention- to- treat analysis and the all- randomised popula-
tion. However, in the unlikely event of a substantial period 
in which any clinic is subsequently unable to implement 
the intervention for any reason then we will also conduct 
an analysis that only includes patients attending the clinic 
while it is able to offer the intervention, in the spirit of 
a per- protocol analysis and a protocol compliant popula-
tion. The inclusion of patients in analysis will not be influ-
enced by whether the patient does or does not take up 
the offer of APT.
Patients who present with conditions managed at first 
attendance as presumptive urogenital chlamydia but who 
subsequently are found to have negative chlamydia tests 
will be excluded from analyses.
trial timeline
There will be a 4- month run in period (July–October 
2018), consisting of rolling clinic set- up including 
training for healthcare professionals and a period of at 
least 2 weeks of baseline data collection when healthcare 
professionals will use RELAY to record standard PN data. 
Research staff will monitor completeness of baseline data 
collection. The data will be used at the end of the trial to 
help interpret the trial findings. Then half of the clinics 
will enter intervention phase while the other half enter 
control phase, according to the randomisation schedule. 
The trial is planned to start 22 October 2018.
At the end of the first 6- month trial phase (October 
2018–April 2019) there will be a 2- week washout period 
where clinics will not offer APT to patients and follow 
their standard PN practice procedures. Clinics which 
start with the control phase will also observe the 2- week 
washout to align the trial time periods. Then clinics cross 
over to the opposite arm (intervention or control) for 
phase two (for 6 months, May–November 2019); patient 
recruitment is planned to end 17 November 2019. The 
total duration of the trial will be 19 months, allowing for a 
3- month follow- up period to enable outcome data collec-
tion to be completed for all patients in the second trial 
phase. Clinics which do not start phase one of the trial in 
November 2018 will complete recruitment in November 
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2019 and trial phases will be condensed. The LUSTRUM 
programme as a whole runs from April 2016 to March 
2021.
Process evaluation
We will conduct an integrated process evaluation, which 
involves a suite of substudies with index patients, sex 
partners and healthcare professionals. In brief these 
studies include: (1) qualitative telephone interviews with 
a sample of index patients who accepted APT for one 
or more sex partner, which will take place up to 8 weeks 
after their first PN consultation; (2) qualitative telephone 
interviews with a sample of sex partners who received 
APT, up to 8 weeks after their APT consultation; (3) qual-
itative telephone interviews with healthcare professionals 
who delivered APT, which take place up to 16 weeks after 
the clinic offers APT during the intervention phase; (4) 
focus groups with healthcare professionals to explore the 
context, extent and fidelity of the intervention delivery, 
which will take place up to 16 weeks after the clinic offers 
APT during the intervention phase.
All potential participants will receive the relevant 
participant information sheet and the researcher will 
discuss this information with participants before seeking 
informed consent to participate (see online supple-
mentary files 2–5). All telephone interviews will be 
audio- recorded with informed verbal consent prior to 
participation, transcribed verbatim and analysed using 
interpretative phenomenological analysis36 to understand 
lived experiences of using APT. The expected duration 
of telephone interviews is 30–60 min. Focus groups will 
be audio- recorded with informed written consent prior to 
participation, transcribed verbatim and data will be anal-
ysed using the Framework approach.37 Data collected will 
assess intervention fidelity, healthcare professionals’ APT 
training (the behaviour change techniques they received) 
and their experience of APT delivery (the behaviour 
change techniques they themselves delivered) in relation 
to a range of feasibility issues such as impact on clinic flow 
and wider systemic and cultural issues.
health economics evaluation
The aim of the economic evaluation is to determine the 
relative cost effectiveness of APT compared with standard 
PN. If APT reduces the number of re- infected cases, there 
will be cost implications for the healthcare sector and for 
society as a whole because of effects on the incidence of 
complications. Cost effectiveness will be determined in 
two ways using two separate economic analyses which 
will explore the costs and consequences of the alterna-
tive interventions and report results in terms of incre-
mental cost effectiveness ratios if applicable. The two 
analyses are: (1) within trial economic evaluation which 
will report the terms of natural units including cost per 
case of re- infection avoided and (2) model- based economic 
evaluation which will report results in terms of cost per 
QALY (Quality- Adjusted Life Year) based on new data 
from recent research.38
The within trial evaluation will use only data collected 
within the trial and will draw on data collected through 
provision of APT up until 4 months postintervention 
when the index cases are re- tested. The evaluation will 
adopt the perspective of the NHS and will be based on 
an outcome of cost per case of re- infection avoided. It is 
acknowledged that this is an intermediate outcome. We 
will build on the experience of exploring the cost effec-
tiveness of alternative versions of APT in previous explor-
atory and pilot studies.25 26
The trial will not capture the effects of APT on the trans-
mission of chlamydia, or on female reproductive tract 
complications, such as PID. As for previous economic 
evaluations of chlamydia screening interventions,39 we 
will develop a dynamic model of the epidemiology of C. 
trachomatis transmission, the APT intervention and its 
outcomes, which will use data from the trial. The model- 
based economic evaluation and deterministic transmis-
sion dynamic model on which the economic evaluation 
will be based, will be reported in detail in a separate 
publication.
trial monitoring
The TMG is responsible for the day- to- day design, delivery 
and management of the trial.
The Trial Steering Committee (TSC) is an executive 
and independent body, providing overall supervision of 
the trial and ensuring that it is being conducted in accor-
dance with the principles of good clinical practice and 
the relevant regulations. The TSC will approve the trial 
protocol and any protocol amendments and provide 
advice to investigators on all aspects of the trial. The TSC 
will monitor trial progress including recruitment, data 
completeness, and losses to follow- up and ensure that 
there are no major and/or unexplained deviations from 
the trial protocol.
The DMC will be responsible for reviewing interim trial 
data and reporting back to the sponsor on the future 
management of the trial. The DMC will use data accu-
mulated throughout the trial to inform guidance and 
recommendations for the continued ethical conduct of 
the trial. The APT intervention is a short, one- off inter-
vention provided to patients as an additional PN option 
which complements existing standard care practices. As 
such, the risk of APT to patients is minimal. We will not 
conduct a formal interim analysis.
We will collect reports of adverse events relating to 
either the intervention or participation in the trial, which 
will be reviewed by the TSC and reported to the sponsor 
and ethics committee as appropriate. The TSC could 
recommend the trial be stopped if members are suffi-
ciently concerned about these events. The trial will not be 
stopped early due to demonstration of efficacy, harm or 
futility in the primary outcome.
Patient and public involvement
The LUSTRUM PPI (Patient and Public Involvement) 
Group consists of 27 lay people, with a broad mix of 
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demographic characteristics and a range of sexual health 
experiences. The group were first involved in the design 
of the research at the grant application stage. Their opin-
ions guided the trial protocol and topic guides for the 
process evaluation interviews. The trial is conducted by 
qualified healthcare professionals and, as such, it is not 
feasible for the group to undertake any aspects of the data 
collection. The group strongly supported the service- 
level consent design which reduces the burden of partici-
pating in the research. Lay summaries of our findings will 
be circulated to the group to gain their perspective and 
feedback on our results; this may inform further analyt-
ical decisions and inputs.
EthICs And dIssEMInAtIon
As this is a pragmatic cluster randomised trial, we will 
seek consent for trial participation from lead clinicians 
at participating clinics (service- level) and will not seek 
individual informed consent from index patients other 
than for the process evaluation studies. Following Weijer 
et al,40 we believe that APT is a complex, ‘low- risk’ health-
care delivery intervention. APT is offered in addition 
to standard PN and operationalised as a supplement to 
usual care, thus index patients have the choice of taking 
up APT or not. It is widely accepted that individual 
consent may not be essential in such trials,41 in which 
the situation is analogous to the introduction of changed 
processes in routine services.31 Notably, individual level 
consent is thought to have contributed to low recruit-
ment numbers in a previous study of APT.26 Individual 
informed consent will be sought from all participants in 
the process evaluation.
Study endpoints, whether negative or positive, will be 
reported and disseminated through the following chan-
nels. (1) Research findings will be published in journals 
with open access within 6 months of publication. (2) 
Research findings will be presented at UK and interna-
tional meetings orally or via posters. (3) A report of the 
findings (in the form of the funder’s final report) will 
be freely available on both the funder’s website and the 
LUSTRUM website after publication in scientific journals. 
A link to the report will be circulated to stakeholders, 
collaborators and participating organisations, together 
with lay summaries of the study on the LUSTRUM 
website. (4) We will make presentations to community 
groups and clinic user groups as appropriate. (5) We will 
make continued use of social media channels to report 
findings after publication in scientific journals, in order 
to increase the ‘reach’ of our findings to the public. (6. 
The anonymised participant level dataset, and statistical 
code for generating the results will be archived in a data 
repository after publication of the final report.
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